Veraxa Biotech to merge with SPAC Voyager in $1.64 billion deal

Reuters
23 Apr
Veraxa Biotech to merge with SPAC Voyager in $1.64 billion deal

April 23 (Reuters) - Switzerland's Xlife Sciences AG XLS.S said on Wednesday its portfolio company, VERAXA Biotech AG, will merge with Voyager Acquisition VACH.O in a deal that will value the combined company at $1.64 billion.

(Reporting by Bipasha Dey in Bengaluru; Editing by Janane Venkatraman)

((Bipasha.Dey@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10